RxDoctor Payments Data

Dominic Pompa, MD

Internal Medicine · Staten Island, NYNPI 1306813696

Payments from drug & device makers

$1,885in general payments, 2019–2025

Across 98 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$993
  • AstraZeneca$587
  • Amgen$114
  • GSK$88
  • MDD US Operations, LLC$29
  • Circassia Inc.$17
  • plus $56 from 4 others

What the payments were for

  • Food & beverage$1,885100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)51$993
AstraZeneca28$587
Amgen7$114
GSK5$88
MDD US Operations, LLC2$29
Circassia Inc.1$17
Lilly USA, LLC1$16
Redhill Biopharma Inc.1$15
Merck1$13
Pfizer1$12

How this compares

$1,885 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$59,410
Medicare patients
101
Services billed
594

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide118$133,227
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate51$117,343
VraylarCariprazine Hcl36$61,284
Diclofenac Potassium23$50,021
EliquisApixaban37$40,883
Diclofenac Sodium72$39,309
JanuviaSitagliptin Phosphate32$32,332
FarxigaDapagliflozin Propanediol48$32,188
OzempicSemaglutide28$29,946
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl146$29,846
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$25,648
Butalbital-AcetaminophenButalbital/Acetaminophen14$22,228
LinzessLinaclotide18$17,855
UbrelvyUbrogepant14$17,189
JardianceEmpagliflozin18$15,102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$16$133,227118 claims
AbbVieVraylar, Linzess, Ubrelvy, Synthroid$993$99,217102 claims
PfizerEliquis, Prempro$12$44,46948 claims
AstraZenecaFarxiga, Symbicort$587$35,31660 claims
MerckJanuvia$13$32,33232 claims
GSKTrelegy Ellipta$88$25,64841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →